Abstract
Coronary artery stenting reduces occlusions after percutaneous coronary intervention (PCI), but obstruction from intimal hyperplasia is still a significant challenge. The glycoprotein IIb/IIIa antiplatelet agent abciximab inhibits inflammatory response and smooth muscle cell proliferation after vascular injury. These authors investigated outcomes with abciximab-coated stents in patients with acute myocardial infarction who required PCI. In a …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
